The ubiquitin-proteasome pathway and proteasome inhibitors

被引:238
|
作者
Myung, J
Kim, KB
Crews, CM [1 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA
[2] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
ubiquitin-proteasome pathway; protein degradation; proteasome inhibitor; natural product;
D O I
10.1002/med.1009.abs
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ubiquitin-proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here. we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various components of the ubiquitin-proteasome pathway. In addition, this review covers the chemistry of synthetic and natural proteasome inhibitors, emphasizing their mode of actions toward the 20S proteasome. Given the importance of proteasome-mediated protein degradation in various intracellular processes, inhibitors of this pathway will continue to serve as both molecular probes of major cellular networks as well as potential therapeutic agents for various human diseases. (C) 2001 John Wiley & Sons. Inc.
引用
收藏
页码:245 / 273
页数:29
相关论文
共 50 条
  • [31] Targeting the ubiquitin-proteasome pathway in breast cancer
    Cardoso, F.
    Piccart, M. J.
    Sotiriou, C.
    Durbecq, V.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 63 - 64
  • [32] The ubiquitin-proteasome pathway and endothelial (dys)function
    Stangl, Karl
    Stangl, Verena
    [J]. CARDIOVASCULAR RESEARCH, 2010, 85 (02) : 281 - 290
  • [33] The ubiquitin-proteasome pathway in Huntington's disease
    Mitra, Siddhartha
    Finkbeiner, Steven
    [J]. THESCIENTIFICWORLDJOURNAL, 2008, 8 : 421 - 433
  • [34] The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer
    Yerlikaya, Azmi
    Kanbur, Ertan
    Stanley, Bruce A.
    Tumer, Emrah
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2021, 21 (01) : 20 - 32
  • [35] β-catenin is a target for the ubiquitin-proteasome pathway.
    Aberle, H
    Bauer, A
    Stappert, J
    Kispert, A
    Kemler, R
    [J]. FASEB JOURNAL, 1997, 11 (09): : A1409 - A1409
  • [36] Degradation of Id proteins by the ubiquitin-proteasome pathway
    Bounpheng, MA
    Dimas, JJ
    Dodds, SG
    Christy, BA
    [J]. FASEB JOURNAL, 1999, 13 (15): : 2257 - 2264
  • [37] Specificity of protein degradation in the ubiquitin-proteasome pathway
    Hao, CM
    He, RQ
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2004, 31 (11) : 975 - 978
  • [38] Ubiquitin-proteasome pathway in skeletal muscle atrophy
    Pang, Xiangsheng
    Zhang, Peng
    Chen, Xiaoping
    Liu, Wenming
    [J]. FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [39] Targeting the ubiquitin-proteasome pathway in cancer therapy
    Ishii, Yuki
    Waxman, Samuel
    Germain, Doris
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (03) : 359 - 365
  • [40] Ethanol and the ubiquitin-proteasome pathway of alveolar macrophages
    D'Souza, Alain Joshua
    Shellito, Judd E.
    Rudner, Xiaowen L.
    Desai, Shyamal
    Ruan, San Bao
    [J]. FASEB JOURNAL, 2009, 23